|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
National Comprehensive Cancer Network:
NCCN Clinical Practice Guidelines in Oncology - Prostate Cancer
(Version 1.2015). PROS–6. http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdfAccessed.
10 01–2015
|
|
3
|
Pound CR, Christens-Barry OW, Gurganus RT,
Partin AW and Walsh PC: Digital rectal examination and imaging
studies are unnecessary in men with undetectable prostate specific
antigen following radical prostatectomy. J Urol. 162:1337–1340.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hong SK, Park HZ, Lee WK, Kim DS, Lee JS,
Doo SH, Jeong SJ, Yoon CY, Byun SS and Lee SE: Prognostic
significance of undetectable ultrasensitive prostate-specific
antigen nadir after radical prostatectomy. Urology. 76:723–727.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
American society for therapeutic radiology
and oncology consensus panel: Consensus statement: Guidelines for
PSA following radiation therapy. Int J Radiat Oncol Biol Phys.
37:1035–1041. 1997.PubMed/NCBI
|
|
6
|
Leibman BD, Dillioglugil O, Wheeler TM and
Scardino PT: Distant metastasis after radical prostatectomy in
patients without an elevated serum prostate specific antigen level.
Cancer. 76:2530–2534. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Leibovici D, Spiess PE, Agarwal PK, Tu SM,
Pettaway CA, Hitzhusen K, Millikan RE and Pisters LL: Prostate
cancer progression in the presence of undetectable or low serum
prostate-specific antigen level. Cancer. 109:198–204. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Oefelein MG, Smith N, Carter M, Dalton D
and Schaeffer A: The incidence of prostate cancer progression with
undetectable serum prostate specific antigen in a series of 394
radical prostatectomies. J Urol. 154:2128–2131. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schriefer P, Steurer S, Huland H and
Graefen M: Is undetectable prostate-specific antigen always
reliable to rule out prostate cancer recurrence after radical
prostatectomy? J Clin Oncol. 30:e341–e344. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jansen FH, Roobol M, Bangma CH and van
Schaik RH: Clinical impact of new prostate-specific antigen WHO
standardization on biopsy rates and cancer detection. Clin Chem.
54:1999–2006. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pound CR, Partin AW, Eisenberger MA, Chan
DW, Pearson JD and Walsh PC: Natural history of progression after
PSA elevation following radical prostatectomy. JAMA. 281:1591–1597.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Moul JW, Wu H, Sun L, McLeod DG, Amling C,
Donahue T, Kusuda L, Sexton W, O'Reilly K, Hernandez J, Chung A and
Soderdahl D: Early versus delayed hormonal therapy for prostate
specific antigen only recurrence of prostate cancer after radical
prostatectomy. J Urol. 171:1141–1147. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Aihara M, Lebovitz RM, Wheeler TM, Kinner
BM, Ohori M and Scardino PT: Prostate specific antigen and gleason
grade: An immunohistochemical study of prostate cancer. J Urol.
151:1558–1564. 1994.PubMed/NCBI
|
|
14
|
Safa AA, Reese DM, Carter DM, Phillipson
J, Smith R and Dougherty S: Undetectable serum prostate-specific
antigen associated with metastatic prostate cancer: A case report
and review of the literature. Am J Clin Oncol. 21:323–326. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Studer UE, Whelan P, Wimpissinger F,
Casselman J, de Reijke TM, Knönagel H, Loidl W, Isorna S, Sundaram
SK and Collette L: EORTC Genitourinary Cancer Group: Differences in
time to disease progression do not predict for cancer-specific
survival in patients receiving immediate or deferred
androgen-deprivation therapy for prostate cancer: Final results of
EORTC randomized trial 30891 with 12 years of follow-up. Eur Urol.
66:829–838. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Warde P, Mason M, Ding K, Kirkbride P,
Brundage M, Cowan R, Gospodarowicz M, Sanders K, Kostashuk E,
Swanson G, et al: NCIC CTG PR.3/MRC UK PR07 investigators: Combined
androgen deprivation therapy and radiation therapy for locally
advanced prostate cancer: A randomised, phase 3 trial. Lancet.
378:2104–2111. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Birtle AJ, Freeman A, Masters JR, Payne HA
and Harland SJ: BAUS Section of Oncology Cancer Registry: Clinical
features of patients who present with metastatic prostate carcinoma
and serum prostate-specific antigen (PSA) levels <10 ng/ml: The
PSA negative patients. Cancer. 98:2362–2367. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Crook JM, OCallaghan CJ, Duncan G,
Dearnaley DP, Higano CS, Horwitz EM, Frymire E, Malone S, Chin J,
Nabid A, et al: Intermittent androgen suppression for rising PSA
level after RT. N Engl J Med. 367:895–903. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Suzman DL and Antonarakis ES:
Castration-resistant prostate cancer: Latest evidence and
therapeutic implications. Ther Adv Med Oncol. 6:167–179. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Moul JW and Dawson N: Quality of life
associated with treatment of castration-resistant prostate cancer:
A review of the literature. Cancer Invest. 30:1–12. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hartsell WF, Scott CB, Bruner DW,
Scarantino CW, Ivker RA, Roach M 3rd, Suh JH, Demas WF, Movsas B,
Petersen IA, et al: Randomized trial of short-versus long-course
radiotherapy for palliation of painful bone metastases. J Natl
Cancer Inst. 97:798–804. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chow E, van der Linden YM, Roos D,
Hartsell WF, Hoskin P, Wu JS, Brundage MD, Nabid A, Tissing-Tan CJ,
Oei B, et al: Single versus multiple fractions of repeat radiation
for painful bone metastases: A randomised, controlled,
non-inferiority trial. Lancet Oncol. 15:164–171. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Timmerman RD, Herman J and Cho LC:
Emergence of stereotactic body radiation therapy and its impact on
current and future clinical practice. J Clin Oncol. 32:2847–2854.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Radiation Therapy Oncology Group: Phase
II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine
Metastasis - RTOG CCOP Study. https://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0631
|
|
25
|
Milano MT, Katz AW, Zhang H and Okunieff
P: Oligometastases treated with stereotactic body RT: Long-term
follow-up of prospective study. Int J Radiat Oncol Biol Phys.
83:878–886. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Salama JK, Kirkpatrick JP and Yin FF:
Stereotactic body RT treatment of extracranial metastases. Nat Rev
Clin Oncol. 9:654–665. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tree AC, Khoo VS, Eeles RA, Ahmed M,
Dearnaley DP, Hawkins MA, Huddart RA, Nutting CM, Ostler PJ and van
As NJ: Stereotactic body RT for oligometastases. Lancet Oncol.
14:e28–e37. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Iyengar P, Kavanagh BD, Wardak Z, Smith I,
Ahn C, Gerber DE, Dowell J, Hughes R, Abdulrahman R, Camidge DR, et
al: Phase II trial of stereotactic body radiation therapy combined
with erlotinib for patients with limited but progressive metastatic
non-small-cell lung cancer. J Clin Oncol. 32:3824–3830. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sweeney C, Chen YH, Carducci MA, Liu G,
Jarrard DF, Eisenberger MA, Wong YN, Hahn NM, Hohli M, Vogelzang
NJ, et al: Impact on overall survival (OS) with chemohormonal
therapy versus hormonal therapy for hormone-sensitive newly
metastatic prostate cancer (mPrCa): An ECOG-led phase III
randomized trial. J Clin Oncol. 32Suppl; 2014 ASCO Annual Meeting
Abstracts; abstr LBA2. (5s)2014.
|
|
30
|
Berkovic P, De Meerleer G, Delrue L,
Lambert B, Fonteyne V, Lumen N, Decaestecker K, Villeirs G, Vuye P
and Ost P: Salvage stereotactic body RT for patients with limited
prostate cancer metastases: Deferring androgen deprivation therapy.
Clin Genitourin Cancer. 11:27–32. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Schroder FH, Hugosson J, Roobol MJ,
Tammela TL, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Määttänen L,
Lilja H, et al: ERSPC Investigators: Screening and prostate cancer
mortality: results of the European Randomised Study of Screening
for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet.
384:2027–2035. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tombal B: Castration-resistant prostate
cancer: Adaptation or clonal selection? Insight from the EORTC
30891 trial. Eur Urol. 66:839–840. 2014. View Article : Google Scholar : PubMed/NCBI
|
